The systems medicine view of semaglutide: from clinical trials to molecular mechanisms
Expert Review of Clinical Pharmacology · 03.07.2026 · 19 (7) · 651-669
DOI: 10.1080/17512433.2026.2695172 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 01.07.2026. Verfasst von Rui Vitorino. Beteiligte Einrichtung: Department of Medical Sciences, iBiMED, University of Aveiro, Aveiro, Portugal. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit nennt 45 Literaturangaben. Gefördert von: FCT – Fundação para a Ciência e a Tecnologia, RISE, Institute of Biomedicine.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, iBiMED, University of Aveiro, Aveiro, Portugal.
- Cardiovascular R&D Centre - UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
Förderung
- FCT – Fundação para a Ciência e a Tecnologia
- RISE
- Institute of Biomedicine
- BUCCAL-PEP
Zitieren
APA
Vitorino, R. (2026). The systems medicine view of semaglutide: from clinical trials to molecular mechanisms. Expert Review of Clinical Pharmacology, 19(7), 651-669. https://doi.org/10.1080/17512433.2026.2695172
Vancouver
Vitorino R. The systems medicine view of semaglutide: from clinical trials to molecular mechanisms. Expert Review of Clinical Pharmacology. 2026;19(7):651-669. doi:10.1080/17512433.2026.2695172
BibTeX
@article{Vitorino2026,
author = {Vitorino, Rui},
title = {The systems medicine view of semaglutide: from clinical trials to molecular mechanisms},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
volume = {19},
number = {7},
pages = {651--669},
doi = {10.1080/17512433.2026.2695172}
}
EUVIMED